Research programme: hepatitis virus gene therapy - Immune Response

Drug Profile

Research programme: hepatitis virus gene therapy - Immune Response

Alternative Names: Hepatitis virus gene therapy research programme - Immune Response

Latest Information Update: 01 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immune Response Corporation
  • Developer Orchestra Therapeutics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Chronic hepatitis

Most Recent Events

  • 01 May 2007 Discontinued - Preclinical for Chronic hepatitis in USA (IV-injection)
  • 31 Dec 2001 This programme is still in active development
  • 20 Sep 1999 Preclinical development for Chronic hepatitis in USA (IV-injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top